0001209191-21-040090.txt : 20210611 0001209191-21-040090.hdr.sgml : 20210611 20210611203801 ACCESSION NUMBER: 0001209191-21-040090 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210609 FILED AS OF DATE: 20210611 DATE AS OF CHANGE: 20210611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Williams Kristen Marie CENTRAL INDEX KEY: 0001296965 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 211012937 MAIL ADDRESS: STREET 1: C/O PACIRA PHARMACEUTICALS, INC. STREET 2: 5 SYLVAN WAY, SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER NAME: FORMER CONFORMED NAME: Dunker Kristen Marie DATE OF NAME CHANGE: 20040712 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-09 0 0001396814 Pacira BioSciences, Inc. PCRX 0001296965 Williams Kristen Marie C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 Chief Administrative Officer Common Stock 2021-06-09 4 A 0 7000 0.00 A 27957 D Common Stock 2021-06-10 4 S 0 4842 59.43 D 23115 D Common Stock 2021-06-10 4 S 0 847 60.57 D 22268 D Stock Option (Right to Buy) 60.96 2021-06-09 4 A 0 17500 0.00 A 2031-06-09 Common Stock 17500 17500 D Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.03 to $59.99, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.20 to $60.92, inclusive. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. /s/ Kristen Williams 2021-06-11